共 50 条
- [41] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229SGarland, LLPegram, MSong, SMendelson, DParker, KEMartell, REGordon, MS
- [42] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid TumorsMOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2825 - 2833Okamoto, IsamuKaneda, HiroyasuSatoh, TarohOkamoto, WataruMiyazaki, MasakiMorinaga, RyotaroUeda, ShinyaTerashima, MasaakiTsuya, AsukaSarashina, AkikoKonishi, KoichiArao, TokuzoNishio, KazutoKaiser, RolfNakagawa, Kazuhiko
- [43] Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Langenberg, M. H.Witteveen, P.Roodhart, J. M.Lolkema, M. P.Verheul, H.Mergui-Roelvink, M.Brendel, E.Kratzschmar, J.Schellens, J. H.Voest, E. E.
- [44] Phase I Study of the Non -Receptor Tyrsine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid TumorsJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S904 - S904Karim, NaglaBahassi, El-MustaphaGaber, OlaSadraei, Nooshin HashemiMorris, John
- [45] A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid TumorsCLINICAL CANCER RESEARCH, 2009, 15 (07) : 2552 - 2558Wong, Kwok-K.Fracasso, Paula M.Bukowski, Ronald M.Lynch, Thomas J.Munster, Pamela N.Shapiro, Geoffrey I.Jaenne, Pasi A.Eder, Joseph P.Naughton, Michael J.Ellis, Matthew J.Jones, Suzanne F.Mekhail, TarekZacharchuk, CharlesVermette, JenniferAbbas, RichatQuinn, SusanPowell, ChristineBurris, Howard A.
- [46] A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Donehower, R. C.Scardina, A.Hill, M.Bowman, J.Newton, R. C.Liu, X.Scherle, P.Wang, Q.Diamond, S.Boer, J.Lee, F.Gau, T.Burris, H. A.Bendell, J. C.Jones, S. F.Infante, J. R.
- [47] Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192SDrevs, JMedinger, MMross, KZirrgiebel, UStrecker, RUnger, CPuchalski, TAFernandes, NRoberston, JSiegert, P
- [48] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 409 - 422Dittrich, ChristianFridrik, Michael A.Koenigsberg, RobertLee, ChooiGoeldner, Rainer-GeorgHilbert, JamesGreil, Richard
- [49] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsInvestigational New Drugs, 2015, 33 : 409 - 422Christian DittrichMichael A. FridrikRobert KoenigsbergChooi LeeRainer-Georg GoeldnerJames HilbertRichard Greil
- [50] Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)Johnson, Melissa LynnePatel, Manish R.Siu, Lillian L.Kozloff, MarkAljumaily, RaidVaishampayan, Ulka N.Elgadi, Mabrouk M.Ge, MiaomiaoDuffy, ChristineGraeser, RalphKhedkar, Sheetal VinayJones, Suzanne FieldsBurris, Howard A.